Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine

By In The News
January 9, 2020 in The Headlines

Recommended Posts

In The News

Posted January 9, 2020

- Share

Posted January 9, 2020

BARCELONA, Spain and SUNNYVALE, Calif., Jan. 9, 2020 /PRNewswire/ -- Almirall, S.A. (ALM), a leading global pharmaceutical company focused on medical dermatology, and 23andMe, the leading consumer genetics and research company, have signed an agreement allowing Almirall to in-license...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219800
2. Jaydee
  16681
3. Kip Powick
  12206
4. deicer
  12171
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.4k

Sign In

Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support